The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery, development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 6600+ highly skilled personnel across 18 facilities including Europe, the US and Asia. Click here to view our facilities.
We have a global reputation for excellence built over 50 years of client service, initially as Galen and then as the wider Almac Group including Galen, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.
Almac is a global provider of pharmaceutical support services with thousands of employees situated throughout its global facilities. It is Almac’s policy to conduct all business in an honest and ethical manner.
The Almac Group is a group of companies operating in the highly regulated and risk-averse pharmaceutical and biotech sectors. We adopt this same low risk strategy in our approach to our tax affairs and tax strategy.
Almac Group is committed to carrying out its business of ethical pharmaceutical products manufacture and services provision in a manner which will not harm its employees, customers, contractors, visitors, neighbours or the environment.
Almac Group is committed to governance of procurement aligned with creating an environment intolerant to criminal conduct, such as any form of modern slavery, corruption or bribery, and minimising or eradicating harmful environmental and social impacts.